Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 11INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × cediranib × 90 days × Clear all
NCT00750841 2026-05-19

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

AstraZeneca

Phase 1 Active not recruiting
64 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡